14-18 October 2020
IN AMI-CS the mortality rate has been approximately 50% for decades. Recent studies (NCSI2, INOVA3 and J-PVAD4) have shown that utilizing best practices with patients in cardiogenic shock have led to demonstrated survival rates of > 70%. Early patient identification with early Impella support, along with the avoidance of inotropes, are just some of the best practices that can lead to improved patient outcomes.
Bill O'Neill on the Achieving >70% AMI-CS Survival Insights from National Cardiogenic Shock Initiative.
Junya Ako, MD provides Insight from J-PVAD STudy: The Efficacy and Safety of ALL Impella Use in Japanese Patients with Drug-Resistant Acute Heart Failure.
Giuseppe Tarantini, MD, PhD, FESC highlights the Importance of Timing and Impact of Extensive Revascularization on Long-term Survival.
Navin Kapur, MD, FAHA, FACC, FSCAI discusses Ventricular Unloading.
Dave Weber, PhD. shares the future of Abiomed's technology for the future of heart recovery. Here you will learn about the Impella 5.5 with SmartAssist and future technologies designed to be SMALL, SMART, and CONNECTED.
CAMP PCI (Coronary Artery & Myocardial Protected PCI) is dedicated to improving patient outcomes and quality of life with supported high-risk PCI by utilizing best practices, techniques and technologies to enable safer, more effective and complete revascularization.FIND OUT MORE
Refererences - 1. Doshi D, et al. J Am Coll Cardiol. 2016;68(5):450-458 2. Basir, M., et al. (2019). Catheter Cardiovasc Interv, 93(7), 1173-1183 3.Tehrani, B., et al. (2019). J Am Coll Cardiol, 73(13), 1659–1669 4. Sawa, Y. (2020). Japanese Circulation Society, Kyoto